"http://www.linkos.cz/po-kongresu/databaze-tuzemskych-onkologickych-konferencnich-abstrakt/abstrakta/cislo/6065/" . "EGFR, KRAS and PIK3CA gene mutations in Patients with squamous NSCLC histology, and their significance for PREDICTION OF TREATMENT EGFR-TKI effect"@en . "MUTACE GENU EGFR, KRAS A PIK3CA U PACIENT\u016E S NSCLC SKVAM\u00D3ZN\u00CD HISTOLOGIE A JEJICH V\u00DDZNAM PRO PREDIKCI EFEKTU L\u00C9\u010CBY EGFR-TKI" . "NSCLC, PIK3CA, EGFR, KRAS"@en . . "Min\u00E1rik, Marek" . "P(NR9087)" . . . . "MUTACE GENU EGFR, KRAS A PIK3CA U PACIENT\u016E S NSCLC SKVAM\u00D3ZN\u00CD HISTOLOGIE A JEJICH V\u00DDZNAM PRO PREDIKCI EFEKTU L\u00C9\u010CBY EGFR-TKI"@cs . . "MUTACE GENU EGFR, KRAS A PIK3CA U PACIENT\u016E S NSCLC SKVAM\u00D3ZN\u00CD HISTOLOGIE A JEJICH V\u00DDZNAM PRO PREDIKCI EFEKTU L\u00C9\u010CBY EGFR-TKI"@cs . . "Tyrozinkinn\u00E1zov\u00E9 inhibitory receptoru pro epiderm\u00E1ln\u00ED r\u016Fstov\u00FD faktor (EGFR-TKI) p\u0159edstavuj\u00ED efektivn\u00ED mo\u017Enost l\u00E9\u010Dbby lokoregion\u00E1ln\u011B pokro\u010Dil\u00E9ho nebo metastatick\u00E9ho stadia NSCLC. Byly identifikov\u00E1ny n\u011Bkter\u00E9 genetick\u00E9 alterace, kter\u00E9 predikuj\u00ED efekt t\u00E9to c\u00EDlen\u00E9 l\u00E9\u010Dby. Aktiva\u010Dn\u00ED mutace genu EGFR p\u0159edstavuj\u00ED v\u0161eobecn\u011B uzn\u00E1van\u00FD prediktor dobr\u00E9ho efektu l\u00E9\u010Dby EGFR-TKI. Dal\u0161\u00ED mutace, jejich\u017E v\u00FDznam je zkoum\u00E1n p\u0159edstavuj\u00ED mutace genu KRAS a genu PIK3CA. Mutace gen\u016F EGFR a KRAS jsou \u010Dast\u00E9 u pacient\u016F s adenokarcinomem, u pacient\u016F se skvam\u00F3znn\u00EDm NSCLC jsou vz\u00E1cn\u00E9 a jejich v\u00FDznam je m\u00E1lo ob\u00ADjasn\u011Bn. C\u00EDlem na\u0161\u00ED pr\u00E1ce bylo objasn\u011Bn\u00ED prediktivn\u00EDho v\u00FDznamu mutac\u00ED EGFR (delece na exonu 19, bodov\u00E9 mutace na exonu 21), KRAS (mutace na exonu 1) a PIK3CA (mutace ne exonu 9) u pacient\u016F s pokro\u010Dil\u00FDm NSCLC, kte\u0159\u00ED byli l\u00E9\u010Deni EGFR-TKI. Soubor geneticky testovan\u00FDch pacient\u016F \u010D\u00EDt\u00E1 celkem 223 pacient\u016F s pokro\u010Dil\u00FDm stadiem NSCLC (stadium IIIB a IV), z toho 179 pacient\u016F bylo l\u00E9\u010Deno EGFR-TKI (erlotinib, gefitinib). Genetick\u00E9 vy\u0161et\u00AD\u0159en\u00ED bylo provedeno metodou denatura\u010Dn\u00ED kapil\u00E1rn\u00ED elektrofor\u00E9zy a PCR sekvenace. Aktiva\u010Dn\u00ED mutace genu EGFR byla prok\u00E1z\u00E1na u 16 (7,2 %) pa\u00ADcient\u016F, mutace KRAS byla prok\u00E1z\u00E1na u 16/215 (7,4 %) pacient\u016F a mutace PIK3CA u 8/208 (3,8 %) pacient\u016F. Nebyl prok\u00E1z\u00E1n v\u00FDznamn\u00FD rozd\u00EDl v PFS (p = 0,425) i OS (p = 0,673) v souvislosti s aktiva\u010Dn\u00ED mutac\u00ED genu EGFR. Nebyl prok\u00E1z\u00E1n v\u00FDznamn\u00FD rozd\u00EDl v PFS (p = 0,12) v souvislosti s mutac\u00ED genu KRAS, ale bylo zde pro\u00ADk\u00E1z\u00E1no krat\u0161\u00ED OS (p = 0,039) u pacient\u016F s KRAS mutac\u00ED. Nebyl prok\u00E1z\u00E1n v\u00FDznamn\u00FD rozd\u00EDl v PFS (p = 0,197) i OS (p = 0,687) v souvislosti s mutac\u00ED genu PIK3CA."@cs . . "MUTACE GENU EGFR, KRAS A PIK3CA U PACIENT\u016E S NSCLC SKVAM\u00D3ZN\u00CD HISTOLOGIE A JEJICH V\u00DDZNAM PRO PREDIKCI EFEKTU L\u00C9\u010CBY EGFR-TKI" . . . . "Tyrosin Kinase inhibitors of the epidermal growth factor receptor (EGFR-TKIs) are effective for teatement of locoregionally advanced or metastatic NSCLC stages. Several genetic alterations that predict the effect of this targeted therapy were identified. Activating mutations in the EGFR serve as generally recognized good predictor of EGFR-TKI treatment efficacy. Another mutation, whose importance is investigated, are KRAS and PIK3CA gene mutations. Mutations in EGFR and KRAS genes are common in patients with adenocarcinoma, but in patients with squamos NSCLCm are rare and their significance is little understood. The aim of our study was to clarify the predictive significance of EGFR mutations (exon 19 deletions, point mutations in exon 21), KRAS (mutation in exon 1) and PIK3CA (no mutation in exon 9) in patients with advanced NSCLC who were treated with EGFR-TKI. Genetic testing: Total: 223 patients with advanced NSCLC (stage IIIB and IV), of which 179 patients were treated with EGFR-TKI (erlotinib, gefitinib). Genetic testing was performed using denaturing capillary electrophoresis and PCR sequencing. Activating mutations in the EGFR gene has been shown in 16 (7.2%) patients KRAS mutation was detected in 16/215 (7.4%) patients, and PIK3CA mutations in 8/208 (3.8%) patients. There was no statistically significant difference in PFS (p = 0.425) and OS (p = 0.673) in connection with EGFR activating mutations. There was no statistically significant difference in PFS (p = 0.12) in connection with KRAS mutations, but there was a demonstrated shorter OS (p = 0.039) in patients with KRAS mutations. There was no statistically significant difference in PFS (p = 0.197) and OS (p = 0.687) in connection with PIK3CA mutations."@en . "[78693034A623]" . . . . "RIV/26475821:_____/13:#0000180!RIV14-MZ0-26475821" . . "6"^^ . "Tyrozinkinn\u00E1zov\u00E9 inhibitory receptoru pro epiderm\u00E1ln\u00ED r\u016Fstov\u00FD faktor (EGFR-TKI) p\u0159edstavuj\u00ED efektivn\u00ED mo\u017Enost l\u00E9\u010Dbby lokoregion\u00E1ln\u011B pokro\u010Dil\u00E9ho nebo metastatick\u00E9ho stadia NSCLC. Byly identifikov\u00E1ny n\u011Bkter\u00E9 genetick\u00E9 alterace, kter\u00E9 predikuj\u00ED efekt t\u00E9to c\u00EDlen\u00E9 l\u00E9\u010Dby. Aktiva\u010Dn\u00ED mutace genu EGFR p\u0159edstavuj\u00ED v\u0161eobecn\u011B uzn\u00E1van\u00FD prediktor dobr\u00E9ho efektu l\u00E9\u010Dby EGFR-TKI. Dal\u0161\u00ED mutace, jejich\u017E v\u00FDznam je zkoum\u00E1n p\u0159edstavuj\u00ED mutace genu KRAS a genu PIK3CA. Mutace gen\u016F EGFR a KRAS jsou \u010Dast\u00E9 u pacient\u016F s adenokarcinomem, u pacient\u016F se skvam\u00F3znn\u00EDm NSCLC jsou vz\u00E1cn\u00E9 a jejich v\u00FDznam je m\u00E1lo ob\u00ADjasn\u011Bn. C\u00EDlem na\u0161\u00ED pr\u00E1ce bylo objasn\u011Bn\u00ED prediktivn\u00EDho v\u00FDznamu mutac\u00ED EGFR (delece na exonu 19, bodov\u00E9 mutace na exonu 21), KRAS (mutace na exonu 1) a PIK3CA (mutace ne exonu 9) u pacient\u016F s pokro\u010Dil\u00FDm NSCLC, kte\u0159\u00ED byli l\u00E9\u010Deni EGFR-TKI. Soubor geneticky testovan\u00FDch pacient\u016F \u010D\u00EDt\u00E1 celkem 223 pacient\u016F s pokro\u010Dil\u00FDm stadiem NSCLC (stadium IIIB a IV), z toho 179 pacient\u016F bylo l\u00E9\u010Deno EGFR-TKI (erlotinib, gefitinib). Genetick\u00E9 vy\u0161et\u00AD\u0159en\u00ED bylo provedeno metodou denatura\u010Dn\u00ED kapil\u00E1rn\u00ED elektrofor\u00E9zy a PCR sekvenace. Aktiva\u010Dn\u00ED mutace genu EGFR byla prok\u00E1z\u00E1na u 16 (7,2 %) pa\u00ADcient\u016F, mutace KRAS byla prok\u00E1z\u00E1na u 16/215 (7,4 %) pacient\u016F a mutace PIK3CA u 8/208 (3,8 %) pacient\u016F. Nebyl prok\u00E1z\u00E1n v\u00FDznamn\u00FD rozd\u00EDl v PFS (p = 0,425) i OS (p = 0,673) v souvislosti s aktiva\u010Dn\u00ED mutac\u00ED genu EGFR. Nebyl prok\u00E1z\u00E1n v\u00FDznamn\u00FD rozd\u00EDl v PFS (p = 0,12) v souvislosti s mutac\u00ED genu KRAS, ale bylo zde pro\u00ADk\u00E1z\u00E1no krat\u0161\u00ED OS (p = 0,039) u pacient\u016F s KRAS mutac\u00ED. Nebyl prok\u00E1z\u00E1n v\u00FDznamn\u00FD rozd\u00EDl v PFS (p = 0,197) i OS (p = 0,687) v souvislosti s mutac\u00ED genu PIK3CA." . "EGFR, KRAS and PIK3CA gene mutations in Patients with squamous NSCLC histology, and their significance for PREDICTION OF TREATMENT EGFR-TKI effect"@en . . "Brno, Brn\u011Bnsk\u00E9 onkologick\u00E9 dny" . . "90230" . . "2"^^ . "Bene\u0161ov\u00E1, Lucie" . "RIV/26475821:_____/13:#0000180" . . .